Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Cathcart, Mary Clare ^a   Gately, Kathy ^a   Cummins, Robert ^b   Kay, Elaine ^b   O'Byrne, Kenneth J ^a   Pidgeon, Graham P ^a  

^a Dublin Molecular Medicine Centre   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; THROMBOXANE B2; THROMBOXANE SYNTHASE; ENZYME INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; TISSUE MICROARRAY; WESTERN BLOTTING; ADENOCARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOXANE B2; THROMBOXANE-A SYNTHASE; TISSUE ARRAY ANALYSIS;

EID: 79952328452     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-25     Document Type: Article

References (36)

1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005, 23:3175-3185. 10.1200/JCO.2005.10.462, 15886304.
2. Spicer J, Chowdhury S, Harper P. Targeting novel and established therapies for non-small cell lung cancer. Cancer Lett 2007, 250:9-16. 10.1016/j.canlet.2006.09.001, 17030089.
3. Carney DN. Lung cancer--time to move on from chemotherapy. N Engl J Med 2002, 346:126-128. 10.1056/NEJM200201103460211, 11784881.
4. Hinz B, Brune K. Cyclooxygenase-2--10 years later. J Pharmacol Exp Ther 2002, 300:367-375. 10.1124/jpet.300.2.367, 11805193.
5. Needleman P, Isakson PC. Selective inhibition of cyclooxygenase-2. Science and Medicine 1998, 26-35.
6. Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Holscher AH, Danenberg KD, Danenberg PV. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002, 235:440-443. 10.1097/00000658-200203000-00017, 1422451, 11882767.
7. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001, 7:861-867.
8. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999, 5:1001-1005.
9. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008, 26:848-855. 10.1200/JCO.2007.13.8081, 18281656.
10. Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008, 14:2088-2094. 10.1158/1078-0432.CCR-07-4013, 18381949.
11. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009, 15:2158-2165. 10.1158/1078-0432.CCR-08-0629, 19276291.
12. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528. 1522 p following 1528, 10.1056/NEJM200011233432103, 11087881.
13. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102. 10.1056/NEJMoa050493, 15713943.
14. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080. 10.1056/NEJMoa050405, 15713944.
15. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004, 10:4266s-4269s. 10.1158/1078-0432.CCR-040014, 15217972.
16. Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 1985, 260:15059-15067.
17. Tanabe T, Ullrich V. Prostacyclin and thromboxane synthases. J Lipid Mediat Cell Signal 1995, 12:243-255. 10.1016/0929-7855(95)00031-K, 8777569.
18. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875. 10.1126/science.294.5548.1871, 11729303.
19. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978, 47:997-1029. 10.1146/annurev.bi.47.070178.005025, 209733.
20. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 2005, 18:221-227. 10.1038/modpathol.3800285, 15475935.
21. Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, Ghoneim MA, Watson DK. Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res 2005, 65:11581-11587. 10.1158/0008-5472.CAN-05-1622, 16357168.
22. Nie D, Che M, Zacharek A, Qiao Y, Li L, Li X, Lamberti M, Tang K, Cai Y, Guo Y, Grignon D, Honn KV. Differential expression of thromboxane synthase in prostate carcinoma: role in tumour cell motility. Am J Pathol 2004, 164:429-439. 10.1016/S0002-9440(10)63133-1, 1602253, 14742249.
23. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumour metastasis. Biochem Biophys Res Commun 2000, 267:245-251. 10.1006/bbrc.1999.1840, 10623605.
24. Sakai H, Suzuki T, Takahashi Y, Ukai M, Tauchi K, Fujii T, Horikawa N, Minamimura T, Tabuchi Y, Morii M, Tsukada K, Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett 2006, 580:3368-3374. 10.1016/j.febslet.2006.05.007, 16709411.
25. Dassesse T, de Leval X, de Leval L, Pirotte B, Castronovo V, Waltregny D. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumour Gleason score and pathologic stage. Eur Urol 2006, 50:1021-1031. discussion 1031, 10.1016/j.eururo.2006.01.036, 16522350.
26. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, Watson DK. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008, 27:55-62. 10.1038/sj.onc.1210629, 17603559.
27. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumour angiogenesis and tumour growth. Cancer Res 2002, 62:63-66.
28. Jantke J, Ladehoff M, Kurzel F, Zapf S, Kim E, Giese A. Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 2004, 146:483-494. 10.1007/s00701-004-0238-z, 15118886.
29. Rieger J, Ohgaki H, Kleihues P, Weller M. Human astrocytic brain tumours express AP02L/TRAIL. Acta Neuropathol 1999, 97:1-4. 10.1007/s004010050948, 9930888.
30. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumours. Clin Cancer Res 2003, 9:1604-1610.
31. Chen GG, Lee TW, Yip JH, Xu H, Lee IK, Mok TS, Warner TD, Yim AP. Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Lett 2006, 234:193-198. 10.1016/j.canlet.2005.03.032, 15876485.
32. Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003, 21:4194-4199. 10.1200/JCO.2003.05.165, 14615447.
33. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004, 2:1760-1765. 10.1111/j.1538-7836.2004.00928.x, 15456487.
34. Li M, Kuo L, Stallone JN. Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression. Am J Physiol Heart Circ Physiol 2008, 294:H2444-2455. 10.1152/ajpheart.01121.2007, 18310519.
35. Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Semin Surg Oncol 2005, 2:23. 10.1186/1477-7800-2-23, 1289289, 16250911.
36. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 2008, 68:4097-4104. 10.1158/0008-5472.CAN-07-6560, 18519668.